First in Europe: All approved CAR-T cell therapy products are available at the University Hospital Leipzig (UKL).

Small glas bottle which is normally used to store vaccine

First in Europe: All approved CAR-T cell therapy products are available at the University Hospital Leipzig (UKL).

{post_date}  •  {terms}

31. December 2022  •  Cell / Gene technology

Chimeric Antigen Receptor T Cell Therapy (CAR-T): Genetically programmed immune cell binds to and destroys cancer cell / Therapy is now available for the majority of indications

Leipzig. Hope for seriously ill patients with hematological cancer: The University Hospital Leipzig (UKL) is the first clinic in Europe to have the opportunity to use all approved CAR T cell therapy products. The last certification process will also be completed in January 2023. This means that those affected can now receive these therapies for a majority of the indications at the clinic and polyclinic for hematology, cell therapy and hemostaseology headed by Prof. Uwe Platzbecker.

Obtaining certification not only means signing a contract with the manufacturer of the respective preparation, but also includes numerous training courses as well as extensive and strict audits, for example by the Paul Ehrlich Institute or the medical service of the health insurance companies. “The last of these audits took place on December 20th and we passed everything with flying colours,” reports Dr. Vladan Vucinic, Senior Physician of the Hematology and cell therapy.

“CAR-T cell therapy is quite complex,” he explains. “The special feature here is that the patient’s own defense cells are used as the starting material.” CAR-T stands for “Chimeric Antigen Receptor T” cell therapy, since it is not an antibody that binds and destroys the cancer cell, but rather the immune cell, i.e. the T cell itself.

“Apheresis, i.e. blood washing, is also done here at the UKL, the associated unit and laboratory are also certified,” emphasizes Dr. Vucinic out.

“We used such a therapy for the first time on a patient in June 300.000, the production costs of which are around 2019 euros. It is now exactly 80,” says senior physician Dr. Vucinic. In cooperation with the Leipzig Fraunhofer Institute for Cell Therapy and Immunology (IZI) and the Institute for Clinical Immunology At the UKL, several research projects are currently running on these therapies, both clinical and translational in nature.

Overview of all certified preparations (trade name, active ingredient) and their areas of application:

  1. Tisagenlecleucel (Kymriah®):
    – Refractory or relapsed B-acute lymphocytic leukemia aged up to 25 years
    – follicular lymphoma after two previous lines of therapy,
    – Aggressive B-cell lymphoma after two previous lines of therapy
  2. Axicabtagene ciloleucel (Yescarta®):
    – aggressive B-cell lymphomas from the second line of therapy,
    – Follicular lymphoma after three previous lines of therapy
  3. Brexucabtagene autoleucel (Tecartus®):
    – mantle cell lymphoma after two previous lines of therapy,
    – Refractory and relapsed B-acute lymphoblastic leukemia in adult patients (over 26 years of age)
  4. Lisocabtagene maraleucel (Breyanzi®):– Aggressive B-cell lymphoma after two previous lines of therapy
  5. Idecabtagene vicleucel (Abecma®):– Multiple myeloma after at least three prior lines of therapy
  6. Ciltacabtagene autoleucel (Carvykti®):– Multiple myeloma after at least three prior lines of therapy

More

Smart Infrastructure Hub in Leipzig receives a further 1,9 million euros in funding

Human who looks onto a recording of brainwaves on his tablet computer and moves the model with his fingers

digital-health

Human who looks onto a recording of brainwaves on his tablet computer and moves the model with his fingers

The Smart Infrastructure Hub Leipzig will receive a further 1,9 million euros from the cluster funding of the Saxon Ministry of Economic Affairs.

BIO-Europe 2022 in Leipzig/Saxony breaks records

Small glas bottle which is normally used to store vaccine

cell-immune-gene-therapies

Small glas bottle which is normally used to store vaccine

A relatively small metropolis in Germany’s Free State of Saxony – a dynamic hub for the life science industry? What was just a vision 20 years ago has become a reality for the city of Leipzig, which from October 24-26 co-hosted BIO-Europe, Europe’s largest annual biotech partnering event.

Leipzig University Hospital again among Germany’s top 10

Woman who looks at something through a microscope while another woman ist watching her

services

Woman who looks at something through a microscope while another woman ist watching her

In the current “Clinic List 2023” of the news magazine FOCUS, the University Hospital Leipzig (UKL) is again one of the TOP 9 of the best hospitals in Germany with 10th place in the nationwide hospital ranking

Back to top